DICE Therapeutics, Inc.
DICENASDAQHealthcare
$47.55
+$0.03(+0.06%)
Market Cap$2.3B
P/E Ratio—
52W High$47.9
52W Low$15.08
DICE Therapeutics, Inc.（DICE）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · DICE · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.01B |
| Gross Margin %(computed) | — | 100.00% | 100.00% | 100.00% |
| Operating Expenses | ||||
| R&D Expenses | $0.06B | $0.04B | $0.02B | $0.02B |
| G&A Expenses | $0.03B | $0.01B | $0.01B | $0.00B |
| Total Operating Expenses | $0.09B | $0.05B | $0.02B | $0.02B |
| Operating Income | ($0.09B) | ($0.05B) | ($0.02B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | -234.58% |
| Interest Income | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.08B) | ($0.05B) | ($0.02B) | ($0.01B) |
| Income Tax Expense | ($0.00B) | ($0.00B) | $0.00B | $0.00B |
| Net Income | ($0.08B) | ($0.05B) | ($0.02B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | -224.48% |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-2.07 | $-3.91 | $-1.02 | $-0.56 |
| Wtd Avg Shares | 0.04B | 0.01B | 0.02B | 0.02B |
| EBITDA | ($0.08B) | ($0.05B) | ($0.02B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | — | -211.36% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · B
深入了解DICE Therapeutics, Inc.
关于DICE Therapeutics, Inc.（DICE）损益表
DICE Therapeutics, Inc.（DICE）损益表数据来源于SEC Form 10-K及10-Q申报文件。2022财年，DICE实现营收$0.00B，毛利润$0.00B（毛利率—），净利润($0.08B)（净利率—）。
常见问题
DICE · 4 问DICE Therapeutics, Inc.（DICE）2022财年营收为$0.00B，同比down100.0%。
DICE revenueDICE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09